A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Genentech

Status: Withdrawn

Conditions: Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT00477425

AVF4223g

Details and patient eligibility

About

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed Informed Consent Form
• Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion criteria

• Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
• Congenital long QT syndrome
• Family history of long QT syndrome
• Clinically significant bradycardia (defined as < 50 beats/minute)